Peer-reviewedCC BY-NC-NDJournal of thoracic disease
Pirfenidone fails to improve outcomes in progressive bronchiolitis obliterans syndrome post-lung transplant.
- 1Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Related
- Pirfenidone in bronchiolitis obliterans syndrome after lung transplantation: two negative trials, one clearer path forward.
- Bronchiolitis Obliterans Syndrome After Allogeneic HSCT: Clinical Characteristics and Survival Outcomes in a Single Center Cohort
- Exercise capacity and handgrip strength following dumbbell-assisted diaphragmatic breathing training in patients with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation: a prospective single-arm study
- Development of a clinical and bronchoalveolar lavage fluid biomarker model for predicting post-infectious bronchiolitis obliterans in hospitalized children
- Reply: Comparative Clinical Outcomes of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis: A Five-Year Real-Life Study
BibTeX
@article{sundar2026pirfenidone,
title = {{Pirfenidone fails to improve outcomes in progressive bronchiolitis obliterans syndrome post-lung transplant.}},
author = {Isaac Kirubakaran Sundar},
journal = {Journal of thoracic disease},
year = {2026},
month = oct,
doi = {10.21037/jtd-2026-2357},
url = {https://europepmc.org/article/MED/42996677},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Pirfenidone fails to improve outcomes in progressive bronchiolitis obliterans syndrome post-lung transplant.
AU - Isaac Kirubakaran Sundar
PY - 2026
DA - 2026/10/16
JO - Journal of thoracic disease
DO - 10.21037/jtd-2026-2357
UR - https://europepmc.org/article/MED/42996677
SN - 2072-1439
SN - 2077-6624
ER -